Article Data

  • Views 650
  • Dowloads 160

Case Reports

Open Access

A rare case of primary ovarian leiomyosarcoma

  • S. Furukawa1,*,
  • K. Hasegawa3
  • Y. Nozawa2
  • Y. Endo1
  • M. Takata1
  • F. Yoshida-Saito1
  • S. Nakamura1
  • R. Yamauchi1

1Obstetrics and Gynecology, Shirakawa Kosei General Hospital, Fukushima, Japan

2Diagnostic Pathology, Shirakawa Kosei General Hospital, Fukushima, Japan

3The Department of Obstetrics and Gynecology, Dokkyo Medical University, Tochigi, Japan

DOI: 10.12892/ejgo4610.2019 Vol.40,Issue 5,October 2019 pp.870-874

Accepted: 08 February 2018

Published: 10 October 2019

*Corresponding Author(s): S. Furukawa E-mail: s-furu@infoseek.jp

Abstract

Primary ovarian leiomyosarcoma (LMS) is very rare, with only 72 cases reported. Its behavior is aggressive, and there is no standard therapy. A 62-year-old woman with a giant pelvic tumor underwent CT and MRI. An irregular, 30-cm, solid tumor that was suspected to be malignant was seen. On laparotomy, the tumor was derived from her right ovary and adhered widely to the retroperitoneum. On pathological examination, it was an ovarian leiomyosarcoma. Adjuvant chemotherapy (docetaxel and gemcitabine) was given. Three months after surgery, CT showed multiple liver metastases. Pazopanib, ifosfamide, doxorubicin, and eribulin were given with no effect, and the woman died 18 months after the primary operation. With the administration of pazopanib, proteinuria of 2.3 g/dl occurred, which made continuous administration impossible. Since ovarian LMS may not respond to chemotherapy for other soft tissue sarcomas, study of more ovarian LMS cases is needed.

Keywords

Primary ovarian leiomyosarcoma (LMS; Laparotomy; Adjuvant chemotherapy; Soft tissue sarcomas

Cite and Share

S. Furukawa, K. Hasegawa,Y. Nozawa,Y. Endo,M. Takata,F. Yoshida-Saito,S. Nakamura,R. Yamauchi. A rare case of primary ovarian leiomyosarcoma. European Journal of Gynaecological Oncology. 2019. 40(5);870-874.

References

[1] Dixit S., Singhal S., Baboo H.A., Vyas R.K., Neema J.P., Murthy R., Sooryanaraya U.: “Leiomyosarcoma of the ovary”. J. Postgrad. Med., 1993, 39, 151.

[2] Tsuyoshi H., Yoshida Y., Kurrokawa T., Kotsuji F.: “Diagnosis and management of leiomyosarcoma arising from ovarian vein: case report and literature review”. J. Obstet. Gynaecol. Res., 2012, 38, 466.

[3] He M., Deng Y.J., Zhao D.Y., Zhang Y., Wu T.: “Synchronous leiomyosarcoma and fibroma in a single ovary: A case report and review of the literature”. Oncol. Lett., 2016, 11, 2510.

[4] Bacalbasa N., Taras C., Orban C., Iliescu L., Hurjui I, Hurjui M., et al.: “Atypical right hepatectomy for liver metastasis from ovarian leiomyosarcoma

[5] Rasmussen C.C., Skilling J.S., Sorosky J.I., Lager D.R., Buller R.E.: “Stage IIIC ovarian leiomyosarcoma in a premenopausal woman with multiple recurrences: prolonged survival with surgical therapy”. Gynecol. Oncol., 1997, 66, 519.

[6] Anderson B., Turner D.A., Benda J.: “Ovarian sarcoma”. Gynecol. Oncol., 1987, 26, 183.

[7] Taskin S., Taskin E.A., Uzum N., Ataoglu O., Ortac F.: “Primary ovarian leiomyosarcoma. A review of the clinical and immunohistochemical features of the rare tumors”. Obstet. Gynecol. Surv., 2007, 62, 480.

[8] Monk B.J., Nieberg R., Berek J.S.: “Primary leiomyosarcoma of the ovary in a perimenarchal female”. Gynecol. Oncol., 1993, 48, 389.

[9] Lerwill M.F., Sung R., Oliva E., Prat J., Young R.H.: “Smooth muscle tumors of the ovary: A clinicopathologic study of 54 cases emphasizing prognostic criteria, histologic variants, and differential diagnosis”. Am. J. Surg. Pathol., 2004, 28, 1436.

[10] Hensley M.L., Barrette B.A., Baumann K., Gaffney D., Hamilton A.L., Kim J.W., et al.: “GCIG Consensus Review: Uterine and ovarian leiomyosarcomas”. Int. J. Gynecol. Cancer, 2014, 24, S61.

[11] Koh W.J., Greer B.E., Abu-Rustum N.R., Apte S.M., Campos S.M., Cho K.R., et al.: “Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines”. J. Natl. Compr. Canc. Netw., 2015, 13, 1321.

[12] Judson I., Verweij J., Gelderblom H., Hartmann J.T., Schöffski P., Blay J.Y., et al.: “Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial”. Lancet Oncol., 2014, 15, 415.

[13] Leyvraz S., Zweifel M., Jundt G., Lissoni A., Cerny T., Sessa C., et al.: “Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas”. Ann. Oncol., 2006, 17, 646.

[14] Sagae S., Yamashita K., Ishioka S., Nishioka Y., Terasawa K., Mori M., et al.: “Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan”. Oncology, 2004, 67, 33.

[15] Yamagami W., Susumu N., Ninomiya T., Kuwahata M., Takigawa A., Nomura H., et al.: “A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma”. Molecul. Clin. Oncol., 2014, 2, 591.

[16] van der Graaf W.T., Blay J.Y., Chawla S.P., Kim D.W., Bui-Nguyen B., Casali P.G., et al.: “Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial”. Lancet 2012, 379, 1879.

[17] Demetri G.D., von Mehren M., Jones R.L., Hensley M.L., Schuetze S.M., Staddon A., et al.: “Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial”. J. Clin. Oncol., 2016, 34, 786.

[18] Schöffski P., Chawla S., Maki R.G., Italiano A., Gelderblom H., Choy E., et al.: “Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomized, open-label, multicenter, phase 3 trial”. Lancet, 2016, 387, 1629.

[19] Sleifer S., Ray-Coquard I., Papai Z., Le Cesne A., Scurr M., Schöffski P., et al.: “Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase 2 study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043)”. J. Clin. Oncol., 2009, 27, 3126.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top